Clinical Trial Update: INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

INTENSE is a Phase I/II study of inhomogeneous targeted dose escalation in non-small cell lung cancer. The trial has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Cancer Trials Ireland | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED